Analysts expect ViewRay, Inc. (NASDAQ:VRAY) to report earnings of -$0.15 per share
Equity research analysts expect ViewRay, Inc. (NASDAQ:VRAY – Get Rating) to report earnings per share of ($0.15) for the current quarter, Zacks reports. Four analysts have made estimates for ViewRay’s earnings, with the highest EPS estimate of $0.14 and the lowest estimate of $0.19. ViewRay reported earnings per share of ($0.18) in the same quarter last year, which would indicate a positive growth rate of 16.7% year over year. The company is expected to announce its next results after the market closes on Thursday, February 24.
On average, analysts expect ViewRay to report full year earnings of ($0.67) per share for the current fiscal year, with EPS estimates ranging from ($0.71) to ($0. $65). For the next fiscal year, analysts expect the company to post earnings of ($0.63) per share, with EPS estimates ranging from ($0.76) to ($0.47). Zacks earnings per share averages are an average average based on a survey of sell-side analysts who provide coverage for ViewRay.
ViewRay (NASDAQ:VRAY – Get Rating) last released its quarterly results on Thursday, February 24. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.01). The company posted revenue of $20.40 million for the quarter, versus analyst estimates of $19.73 million. ViewRay had a negative return on equity of 79.12% and a negative net margin of 159.97%. The company’s quarterly revenue increased by 10.3% compared to the same quarter last year. During the same period last year, the company achieved EPS ($0.18).
VRAY has been the subject of a number of research analyst reports. Zacks Investment Research downgraded ViewRay shares from a “buy” rating to a “hold” rating in a Thursday, January 13 research note. B. Riley moved ViewRay shares from a “neutral” rating to a “buy” rating and set a target price of $7.00 for the company in a Tuesday, January 11 research report. Piper Sandler raised her price target on ViewRay shares from $8.00 to $9.00 and gave the stock an “overweight” rating in a Friday, Nov. 5 research report. Finally, Stifel Nicolaus assumed coverage on ViewRay in a research note on Tuesday, January 25. They set a “buy” rating and a target price of $7.00 for the company. Two equity research analysts gave the stock a hold rating and five gave the stock a buy rating. Based on data from MarketBeat.com, ViewRay currently has an average rating of “Buy” and a consensus price target of $7.21.
The NASDAQ VRAY opened at $3.96 on Friday. ViewRay has a 12 month minimum of $3.48 and a 12 month maximum of $8.25. The company has a 50-day moving average of $4.65 and a 200-day moving average of $5.61. The company has a debt ratio of 0.49, a current ratio of 3.72 and a quick ratio of 3.08. The company has a market capitalization of $652.38 million, a P/E ratio of -5.74 and a beta of 0.81.
A number of institutional investors have recently bought and sold shares of VRAY. Legal & General Group Plc strengthened its position in ViewRay by 45.3% in the 2nd quarter. Legal & General Group Plc now owns 19,614 shares in the company valued at $129,000 after buying an additional 6,115 shares in the last quarter. Dimensional Fund Advisors LP increased its position in ViewRay by 17.5% during the second quarter. Dimensional Fund Advisors LP now owns 1,366,145 shares of the company worth $9,018,000 after acquiring 203,405 additional shares in the last quarter. ProShare Advisors LLC increased its position in ViewRay by 9.5% during the second quarter. ProShare Advisors LLC now owns 35,345 shares of the company worth $233,000 after acquiring 3,057 additional shares in the last quarter. Vanguard Group Inc. increased its position in ViewRay by 13.7% during the second quarter. Vanguard Group Inc. now owns 6,733,109 shares of the company worth $44,439,000 after acquiring an additional 812,749 shares in the last quarter. Finally, Geode Capital Management LLC increased its stake in ViewRay shares by 9.2% in the 2nd quarter. Geode Capital Management LLC now owns 2,158,271 shares of the company valued at $14,244,000 after purchasing an additional 181,154 shares in the last quarter. 89.27% of the shares are held by hedge funds and other institutional investors.
ViewRay Company Profile (Get a rating)
ViewRay, Inc designs, manufactures and markets a magnetic resonance imaging (MRI) system. He is developing MRIdian to address the limitations of existing external beam radiation therapy technologies and uses MRI-based technology to provide real-time imaging that defines the tumor from surrounding soft tissues and other critical organs, at the both before and during the administration of radiotherapy. .
Get a Free Copy of Zacks Research Report on ViewRay (VRAY)
For more information on Zacks Investment Research’s research offerings, visit Zacks.com
This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Should you invest $1,000 in ViewRay right now?
Before you consider ViewRay, you’ll want to hear this.
MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and ViewRay wasn’t on the list.
Although ViewRay currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the 5 actions here